- Does pioglitazone stop the progression of lichen planopillaris? (PILS)
Lead investigator: Dr Vinod Elangasinghe
Intervention: Pioglitazones for adults with active lichen planopillaris.
Status: Not yet presented to Steering group. Trial development group being formed to conduct pilot.
- What is the cost-effectiveness for specialist clothing compared to normal care of children with moderate to severe eczema?
Lead Investigator: Dr Kim Thomas, Nottingham
Intervention: Use of specialist clothing such as Dermasilk® and Comfifast® and compare with normal treatment over six months.
Status: In early development to find the best question to address regarding clothing treatments for eczema. If you are interested in this work and would like more information please contact Dr Kim Thomas.
-
Can statins be used to treat psoriasis?
Lead Investigator: Dr Katherine Finucane, Bristol
Intervention: Statin (to be decided) versus placebo
Outcomes: Improvement in PASI by 50% and a change in DLQI.
Status: A feasibility study has been recommended for this idea. Please contact Margaret McPhee for more information about this study.
-
Skin Cancer Prevention: Does topical field-directed treatment of skin bearing multiple actinic keratosis reduce subsequent development of invasive SCC?
Lead Investigator: Dr Charlotte Proby, Ninewells Hospital, Dundee
Interventions: Topical treatment of precancerous field change on sun exposed areas of skin bearing multiple actinic keratoses with 5% imiquimod cream or with 5% fluorouracil cream or with 3% diclofenac gel and comparison with supervised use of high sun-protection factor sunscreen alone.
Outcomes: Rate of development of cutaneous SCC over 12 months. Clearance of actinic keratoses (AK) at six months and persistance of clearance over one year. The cost effectiveness of these therapies, in terms of AK clearance.
A feasibility study has been recommended for this research idea but Dr Proby has failed to secure funding for this so it is currently on hold and replaced with an alternative idea - Skin cancer Prevention in Organ Transplant patients (SPOT). Please contact Margaret McPhee if you would like more information about this study.
